Shares of Syndax Pharmaceuticals (SNDX) have risen 2.2% in the past four weeks, closing at $9.57. Analysts predict a potential upside of 237.8%, with a mean price target of $32.33. Despite skepticism, a consensus among analysts suggests better earnings than previously estimated. The standard deviation indicates the level of agreement among analysts.

Price targets are often misleading, with analysts sometimes setting overly optimistic targets to generate interest in certain stocks. However, a low standard deviation suggests a high level of agreement among analysts, making it a good starting point for further research. While price targets should not be ignored, they should be viewed with skepticism when making investment decisions.

Analysts’ optimism about Syndax Pharmaceuticals’ earnings prospects is reflected in higher EPS estimates. The Zacks Consensus Estimate for the current year has increased by 0.5% in the past month, with a Zacks Rank #2 (Buy). This suggests a potential upside in the near term, supported by a strong track record of externally-audited performance.

A small number of stocks are poised for a breakout, with 7 selected as compelling buys likely to outperform the market. These stocks are part of Zacks Rank #1 Strong Buys, offering potential for significant gains. Investors can access detailed information on these stocks in the “7 Best Stocks for the Next 30 Days” Special Report.

For investors seeking potential breakout stocks, Syndax Pharmaceuticals (SNDX) is one to watch. With a consensus price target indicating a significant upside, supported by analysts’ positive earnings revisions and a strong Zacks Rank, the stock shows promise for future growth.

Read more at Nasdaq: Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here’s What You Should Know